The research company Peptonic Medical has appointed Daniel Rudeklint as interim CEO with immediate effect, and he thereby replaces Anna Linton as CEO. This is stated in a press release."On behalf of the board, I thank Anna for the work she has done over the past year as CEO of Peptonic and how she has shown commitment and loyalty to the company", says Chairman of the Board Anders Blom.The company announced at the end of August last year that Anna Linton would resign at her own request. The work to recruit a new permanent CEO is ongoing.Daniel Rudeklint has served on the board of Peptonic since January 2023 and is described as having a very strong financial background, very good insight into the company, and solid experience in leading organizations.